Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

6.265 -0.315 (-4.79%)
Streaming Delayed Price Updated: 3:34 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,806,435
Open 6.620
Bid (Size) 6.260 (4)
Ask (Size) 6.270 (7)
Prev. Close 6.580
Today's Range 6.100 - 6.790
52wk Range 2.090 - 14.84
Shares Outstanding 70,902,191
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
3 Undervalued Biotech Stocks With Breakout Potential
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
Via InvestorPlace

Performance

YTD
-40.45%
-40.45%
1 Month
-12.99%
-12.99%
3 Month
-2.03%
-2.03%
6 Month
-38.15%
-38.15%
1 Year
+89.27%
+89.27%

More News

Read More
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
Via InvestorPlace
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
Via InvestorPlace
MarketBeat Week in Review – 7/1 - 7/5
Via MarketBeat
Topics Economy
Exposures Interest Rates
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, Harbor Diversified, Altimmune, and Sprout Social and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
From Law Offices of Frank R. Cruz
Via Business Wire
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Via MarketBeat
Exposures Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Via MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Via MarketBeat
Exposures Product Safety
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Via The Motley Fool
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Via The Motley Fool
Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Via InvestorPlace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
From Faruqi & Faruqi LLP
Via GlobeNewswire
Why Are Altimmune Shares Trading Lower Wednesday?
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.